Home › Compare › CYTR vs ORCC

CYTR vs ORCC: Dividend Comparison 2026

CYTR yields 11620.00% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CYTR wins by $242484085295883808.00M in total portfolio value
10 years
CYTR
CYTR
● Live price
11620.00%
Share price
$0.09
Annual div
$10.46
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$242484085295883808.00M
Annual income
$238,447,405,964,682,430,000,000.00
Full CYTR calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — CYTR vs ORCC

📍 CYTR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCYTRORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CYTR + ORCC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
CYTR pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYTR
Annual income on $10K today (after 15% tax)
$987,700.00/yr
After 10yr DRIP, annual income (after tax)
$202,680,295,069,980,070,000,000.00/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, CYTR beats the other by $202,680,295,069,980,070,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYTR + ORCC for your $10,000?

CYTR: 50%ORCC: 50%
100% ORCC50/50100% CYTR
Portfolio after 10yr
$121242042647941904.00M
Annual income
$119,223,702,982,341,220,000,000.00/yr
Blended yield
98.34%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

CYTR
Analyst Ratings
6
Buy
1
Hold
Consensus: Buy
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYTR buys
0
ORCC buys
0
No recent congressional trades found for CYTR or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCYTRORCC
Forward yield11620.00% ✓9.79%
Annual dividend / share$10.46 ✓$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0% ✓-50%
Portfolio after 10y$242484085295883808.00M ✓$21.4K
Annual income after 10y$238,447,405,964,682,430,000,000.00 ✓$1.04
Total dividends collected$242216106432564192.00M ✓$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: CYTR vs ORCC ($10,000, DRIP)

YearCYTR PortfolioCYTR Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$1,172,700$1,162,000.00$11,190$489.61+$1.16M → CYTR
2$128,607,817$127,353,028.04$12,229$256.01+$128.60M → CYTR
3$13,190,478,160$13,052,867,796.09$13,216$130.74+$13190.46M → CYTR
4$1,265,280,964,319$1,251,167,152,687.08$14,207$66.02+$1265280.95M → CYTR
5$113,519,013,580,267$112,165,162,948,446.42$15,234$33.17+$113519013.57M → CYTR
6$9,526,401,425,885,696$9,404,936,081,354,810.00$16,317$16.62+$9526401425.87M → CYTR
7$747,812,665,514,758,900$737,619,415,989,061,100.00$17,468$8.32+$747812665514.74M → CYTR
8$54,914,516,334,558,180,000$54,114,356,782,457,390,000.00$18,695$4.16+$54914516334558.16M → CYTR
9$3,772,597,505,795,689,000,000$3,713,838,973,317,711,700,000.00$20,006$2.08+$3772597505795689.00M → CYTR
10$242,484,085,295,883,800,000,000$238,447,405,964,682,430,000,000.00$21,407$1.04+$242484085295883808.00M → CYTR

CYTR vs ORCC: Complete Analysis 2026

CYTR — Stock

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.

Full CYTR Calculator →

ORCC — BDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this CYTR vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYTR vs SCHDCYTR vs JEPICYTR vs OCYTR vs KOCYTR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.